May 10, 2018 / 10:52 AM / 2 months ago

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

May 10 (Reuters) - Ligand Pharmaceuticals Inc:

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING

* LIGAND PHARMACEUTICALS INC - KSQ TO BE ABLE TO USE CO'S FULL OMNIAB PLATFORM TO DISCOVER ANTIBODIES

* LIGAND - RECEIVED UPFRONT PAYMENT, ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT & REGULATORY MILESTONE PAYMENTS AMONG OTHERS

* LIGAND PHARMACEUTICALS INC - KSQ TO BE RESPONSIBLE FOR ALL COSTS RELATED TO ITS ANTIBODY DEVELOPMENT PROGRAM Source text: [bit.ly/2rzArcO] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below